1. Introduction {#sec1}
===============

Gastric bypass (GBP) surgery markedly reduces body weight with predominant losses of body fat and smaller reductions of lean body mass and bone mass \[[@B1]\]. The efficiency of GBP in treating morbid obesity is widely recognized, and its effect to improve glucose intolerance and diabetes is remarkable. In addition to the caloric restriction imposed by the operation, altered gastrointestinal hormonal signalling \[[@B2]--[@B4]\] is generally thought to contribute to the beneficial effect of GBP in resolving diabetes \[[@B5], [@B6]\].

In a recent study using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), we observed a larger relative reduction in visceral fat depot than subcutaneous fat at one month following GBP, and furthermore, an unexpected lack of change in liver fat \[[@B7]\]. At this time point, the morbidly obese subjects had lost an average of four BMI units, and the insulin sensitivity, as calculated by HOMA index, had improved by 34%. Fasting concentrations of free fatty acids (FFA) and beta-hydroxybutyric acid were elevated, reflecting lipolysis and flux of free fatty acids to the liver. In general, an inverse relationship between liver fat content and insulin sensitivity has been described \[[@B8], [@B9]\]. In this regard, the situation observed one month after GBP represents a notable disconnect.

Short periods of low-calorie diet (LCD) prior to gastric bypass are increasingly recommended by surgeons in order to preoperatively reduce body weight and liver volume and thereby facilitate the surgical procedure \[[@B10], [@B11]\]. To provide further insights into lipid dynamics after GBP, we evaluated a group of morbidly obese women prior to one month of preoperative LCD, at surgery, and one month after the GBP. The metabolic balance was examined by blood tests, and changes of the lipid depots were analyzed with a novel MRI setup, including postprocessing and MRS. Significant differences between the two treatment periods with respect to the changes in total amount of body fat as well as liver fat were observed.

2. Materials and Methods {#sec2}
========================

2.1. Subjects and Study Design {#sec2.1}
------------------------------

Fifteen morbidly obese women with the characteristics summarized in [Table 1](#tab1){ref-type="table"} were recruited from the waiting list for laparoscopic gastric bypass at the Department of Surgery, University Hospital in Uppsala, Sweden. None of the subjects had a specific hepatic disease disorder resulting in fatty liver or a history of alcohol abuse. The local ethics committee approved the study, and written consent was obtained from all subjects. This study was performed also to determine to what extent a one-month LCD treatment would reduce liver volume and facilitate the surgical procedures (to be published).

The study procedures were based on three main visits, separated by one month. At each of these visits, blood samples were drawn after overnight fasting. MR investigations were performed at the same day in a fed state. *First visit:* MRI/MRS was carried out in the forenoon, and the LCD treatment was initiated, after consultation with a dietician, during the afternoon. To increase motivation and thereby improve LCD compliance, a meeting with a dietician was held after approximately one week of LCD. *Second visit:* MRI/MRS was performed in the evening and the GBP the following day. *Third visit:* MRI/MRS was performed in the afternoon.

2.2. Low-Calorie Diet {#sec2.2}
---------------------

LCD treatment (Modifast, Inpolin AB, Stockholm) was initiated one month prior to the GBP. All participants received information and instructions from the same physician and a trained dietician. The LCD regimen ad modum Modifast, containing 30 E% protein, 49 E% carbohydrates, and 21 E% fat, was prescribed. Total calorie intake was set to total energy expenditure, as calculated by Harris-Benedict, minus 1000 kcal/day. A lower limit of 860 kcal/day was used. The resulting total calorie intake averaged 959 ± 149 kcal/day.

2.3. Surgery {#sec2.3}
------------

Laparoscopic gastric bypass surgery was performed at the Department of Surgery, Uppsala University Hospital according to clinical routine \[[@B12]\]. A five-port technique with circular stapling of the gastrojejunostomy was used. The proximal jejunum was divided 30 cm distal to the ligament of Treitz, and a 70-cm Roux-limb was created. The small bowel continuity was restored by an enteroanastomosis. The left liver lobe was then elevated by an Endopaddle (Ethicon Endosurgery, Johnson&Johnson, Cincinnati, OH). The angle of His was opened as well as the bursa five cm distal to the gastroesophageal junction on the lesser curvature. The pouch was divided by a horizontal 45 mm cutting linear stapler and two vertical 60 mm rows. The anvil of the 25 mm circular stapler was passed transorally and placed in the right-angled corner in-between the two first stale lines. The Roux-limb was passed anticolic, antigastric and anastomosed to the pouch end-to-side by the circular stapler (Covidien, Norwalk, CT). Finally, the anastomosis was checked by air under water, and the portholes were closed. The patients were given preoperative antibiotics and thromboprophylaxis by subcutaneous low-molecular-weight heparin (LMWH) for 14 days. In each recruited patient, the laparoscopic gastric bypasses could be performed and the postoperative course was uneventful, except in one patient who had the enteroanastomosis corrected.

2.4. Blood Analyses {#sec2.4}
-------------------

Blood was collected after an overnight fast, and serum and plasma were prepared and stored at −70°C until analysis. Fasting plasma glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), free fatty acids (FFA), apolipoproteins A1 and B, and liver enzymes were measured with routine laboratory techniques. Insulin was analyzed with an AutoDELFIA automatic immunoassay system (Wallac Oy, Turku, Finland). Growth hormone (GH), glucagons, and NT-pBNP were determined with assays in routine use at Clinical Chemistry, Uppsala University Hospital. Beta-hydroxybutyrate was spectrophotometrically determined in plasma with an enzymatic end-point method \[[@B13]\]. Leptin and adiponectin were analyzed in plasma samples as previously described \[[@B14]\]. The homeostasis model assessment (HOMA, mmol/L) index was calculated by multiplying fasting plasma glucose mmol/L and fasting insulin mU/L and then dividing by 22.5 \[[@B15]\].

2.5. Magnetic Resonance Acquisition {#sec2.5}
-----------------------------------

The MR measurements were performed using a 1.5T clinical scanner (Achieva; Philips Healthcare, Best, The Netherlands) modified to allow imaging during arbitrary table speed. A special 3D gradient echo sequence was used to collect three images with different echo times (TE) from each axial slice during continuous table motion \[[@B16]\]. Imaging parameters were as follow: TR 5.9 ms, TE 1.36/3.22/5.09 ms, flip angle 3 degrees, elementary signal sampling field of view (FOV) (in motion direction) 112 mm, virtual FOV 530 × 377 × 2000 mm^3^, and voxel size 2.07 × 2.07 × 8.00 mm^3^. The table speed was set to 6.5 mm/s resulting in a whole-body scan time of 5 min, 15 sec. Shallow breathing was instructed during acquisition of the abdominal region to reduce potential respiration inducing motion artefacts. Subjects were imaged in supine position with the arms extended above the head.

To evaluate liver fat, single-volume localized ^1^H-spectroscopy was performed in a 3 × 3 × 3 cm^3^ volume of interest positioned in the right liver lobe, avoiding major vessels and bile ducts. A PRESS acquisition was used with the parameters TR/TE, 3000/44 ms, with 16 excitations without water suppression and 32 with water suppression (1024 samples, 1000 Hz bandwidth) during free shallow breathing.

2.6. Magnetic Resonance Data Processing {#sec2.6}
---------------------------------------

Whole-body water and fat images were reconstructed using the multiecho image data as previously described \[[@B17]\]; see [Figure 1](#fig1){ref-type="fig"}. Visceral and abdominal subcutaneous adipose tissue (VAT and SAT) was automatically measured from the reconstructed water and fat images as previously described \[[@B16]\]. Coefficients of variation (CVs) of repeated investigations have previously been determined to be 2.3% ± 2.6% and 2.3% ± 2.1%, for VAT and SAT, respectively. Estimates of total fat and water volumes were calculated by summing the signals in the fat and water fraction images, respectively \[[@B16]\]; see [Figure 1](#fig1){ref-type="fig"}. To reduce the effect from differences in the amount of arms and feet included in the image volumes only, manually determined subvolumes (from the top of the head to the axial slice above the feet with "smallest areas") were analyzed. The fat volume is derived mainly from adipose tissues while the water volume originates mainly from lean tissue.

Spectroscopy data was analyzed using jMRUI \[[@B18]\] (version 3.0; [www.mrui.uab.es](www.mrui.uab.es)), employing water as internal reference, facilitating liver fat measures in percent. Spectral line intensities were determined by time domain fitting, using the nonlinear least-squares AMARES algorithm \[[@B19]\]. No spectral preprocessing was applied.

Liver volumes were assessed by manual segmentation in axial slices of the reconstructed water images by two experienced operators using the software ImageJ (version 1.40 g, <http://rsbweb.nih.gov/ij/>). Average liver volumes were used. The liver fat assessment using MRS gives liver fat concentration (%). If this concentration changes, one does not know if that is a result of change in liver fat content or if the total liver volume has changed for other reasons. Since liver volume was also assessed in this study, the total liver fat volume was calculated by multiplying concentration and volume.

2.7. Statistics Analysis {#sec2.7}
------------------------

Two-sided, paired *t*-tests were used to test for differences between absolute values between the time points in [Table 1](#tab1){ref-type="table"} and between relative changes in [Table 2](#tab2){ref-type="table"}. *P* values of \<.05 were considered statistically significant.

3. Results {#sec3}
==========

The patients lost comparable amounts of body weight during the two months, on average 7.47 ± 2.59 kg during the first month with LCD and 8.09 ± 1.70 kg during the postoperative month (*P* = .497/.148, for absolute/relative changes, resp., *n* = 15). The weight reductions in 13 subjects successfully analyzed with MRI/MRS were 8.03 ± 2.28 and 8.03 ± 1.76 kg, respectively. The relative decrease in total body fat was greater during the GBP month (from −7.1% ± 3.6% to −10.0 ± 3.2%, *P*  = .029, *n* = 13). The reductions in the visceral and abdominal subcutaneous fat depots were on average −7.3% and −6.6%, respectively, after LCD and −10.3% and −10.3% after GBP. The estimated water volumes showed similar changes during the LCD and the GBP month, −4.8% and −5.0%, respectively.

The measurements at the different time points are shown in [Table 1](#tab1){ref-type="table"} and the relative changes in [Table 2](#tab2){ref-type="table"}. The MRI/MRS data is reported for the 13 subjects successfully analysed at all three time points. One subject cancelled all MR investigations and another subject cancelled her third. The relative mean changes in weight, total fat and water volumes and also in liver fat are shown in [Figure 2](#fig2){ref-type="fig"}. The absolute fat volumes and liver fat measurements are shown in Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, respectively.

Liver volume decreased significantly over the LCD-month but not during the GBP month. Corresponding changes in liver fat were determined to be −40.6% ± 25.3%, (*P* = .001) and +12.4% ± 51.7%, (*P* = .736).

Biochemically, alterations in fasting glucose and insulin levels took place during the two periods, resulting in increased insulin sensitivity as reflected by the HOMA indices. Free fatty acids concentrations increased from 0.58 to 0.85 mmol/L after LCD and to 0.89 mmol/L one month after the operation. The beta-hydroxybutyrate concentrations increased by several folds during LCD, from a mean of 0.07 to 0.31 umol/L and remained elevated one month after surgery, 0.34 umol/L.

The patients studied had, at baseline, cholesterol and apolipoprotein A and B within the normal reference ranges and slightly elevated triglycerides. After diet and surgery, changes within the reference ranges were noted. Leptin fell during both LCD and GBP. Adiponectin tended to increase after LCD and was not further altered over the postoperative month. Mean values of growth hormone prior to LCD, at surgery, and at one month after GBP were 0.46, 1.05, and 1.49 ug/L, glucagon 73, 69, and 76 pmol/L, and NT-pBNP 45, 46, and 94 ng/L, respectively.

Alanine transaminase (ALT) increased after LCD from 0.43 to 0.93 *μ*kat/L and fell into the normal range to 0.57 the month after surgery. Aspartate aminotransferase (AST) and gamma glutamyltransferase (GT) showed similar patterns of lesser magnitude.

4. Discussion {#sec4}
=============

The extent of weight loss after the month with LCD and that at the first month after GBP were similar, yet the mobilization of body fat was larger after the operation than after the LCD. Furthermore, the amount of liver fat was not lowered one month after GBP, which it was after the month of LCD. Free fatty acids and the beta-hydroxybuturate concentrations were elevated and tended to be higher one month after GBP, compared to after one month of LCD. Collectively, the findings indicate a more marked flux of fatty acids from the adipose tissues to the liver and subsequent incorporation into triglycerides during the month after GBP compared to the LCD month.

A limitation of the design used in this study is that the effects seen during the month after GBP are not only influenced by the GBP surgery but also by effects of the preoperative LCD. The restriction of the caloric intake during the preoperative LCD month most likely reduces the initial lipolytic effects seen after GBP. Despite this, the results from the current study indicate instead an increased lipolysis after GBP.

The observation of unchanged liver fat one month after surgery is in good agreement with our previous prospective report on lipid mobilization over a year-long period after GBP, in which at one month after surgery, there likewise was no change in liver fat, despite marked changes in subcutaneous and visceral depots \[[@B7]\]. The patients of the previous study were also of female gender and had similar age, weight, and BMI (35 years range 22--47, 122 ± 13 kg, and 43.7 ± 4.1 kg/m^2^, resp.) as the subjects of this study. Thereby, they can be regarded as a historical control group of obese subjects undergoing gastric bypass without a preoperative LCD period. These subjects lost, on average, 11.0 kg body weight and 8.4 liters of adipose tissue (also assessed using whole-body MRI) the first month after GBP. This should be compared to the reductions of 7.4 kg body weight and 5.0 liters of adipose tissue measured after the LCD month in the current study. It seems likely that the lesser degree of weight loss during the month after GBP in the present study is influenced by the prior weight loss that took place during the preoperative LCD month.

The similar weight losses measured in this study suggest that the caloric intakes over the two periods were comparable. Average caloric intake three to six months after gastric bypass surgery has been estimated to be 960--1000 kcal/day \[[@B20], [@B21]\], that is, close to that of the LCD employed (average 959 kcal/day). The patients were advised a diet with an energy content and macronutrient composition similar to that of the LCD. After an operation, patients typically take multiple, small meals in order to lower a risk of dumping and/or postprandial hypoglycemic episodes. We did not collect dietary records in attempts to calculate detailed energy, protein, lipid, and carbohydrate intake.

To account for the larger reduction in fat after GBP compared to the LCD period but similar weight losses during the two periods, a somewhat larger reduction in nonfat compartments should have taken place during the LCD month. With the MRI technique used, only two compartments are visualized as images generated from protons in fat and water molecules. The fat volumes primarily reflect the adipose tissue even though bone marrow and fatty infiltrated tissues/organs also contribute. The water volumes reflect the nonfat lean tissue of muscles, organs, and brain. Bone marrow and water content in adipose tissue also contribute. In this study, the change in water volumes did not differ between the LCD and GBP months, in contrast to the change in fat volumes. A limitation of our study is that we did not perform any measurements by DEXA, which would provide information on changes in lean tissue and bone.

There was an increase in liver enzymes during LCD and a trend towards normalization over the month following the operation. In general, morbid obesity is associated with some degree of steatohepatitis and elevation of liver enzymes, changes that improve upon long-term weight loss \[[@B22]\]. Marked diet-induced weight loss over shorter periods of time has been found to increase liver enzymes \[[@B23], [@B24]\] by mechanisms that are not fully understood \[[@B25]\]. In some studies, the increase in enzymes has been transitory and suggested to reflect an adaptation of the hepatocytes. In this study, the difference in enzyme levels one month after LCD compared to one month after GBP might reflect such adaptation, as the daily average intake and composition of nutrients supposedly were similar during the two periods. In support of such notion, we have observed that patients operated with gastric bypass without a preoperative LCD treatment and examined one month after the operation displayed elevated liver enzymes (unpublished).

Any caloric restriction causes a breakdown of fat, driven by hormone-sensitive lipase in adipocytes and by lipoprotein lipase in heart and skeletal muscles. Lipolysis in white adipose tissue is mainly controlled by the antilipolytic effect of insulin and a stimulatory effect of norepinephrine released from sympathetic nerve endings and acting via beta-adrenergic receptors \[[@B26]\]. Lipolysis is also influenced by humoural factors such as circulating catecholamines, growth hormone, thyroid hormones, and glucagon. Recently, natriuretic peptides have been added to the list of lipolytic hormones \[[@B27]\]. In this study, GH baseline concentrations increased throughout and thereby conceivably contributed to promote lipolysis. Increases in GH levels after GBP have been described by us \[[@B28]\] and others \[[@B29]\]. The BNP levels were unchanged during the LCD month while they were seen to increase during the GBP month. We are not aware of any prior reports of BNP levels determined after gastric surgery.

In a recent report, centrally administered GLP-1 was found to stimulate sympathetic flow and lipolysis of body fat \[[@B30]\]. An increased secretion of GLP-1 is a prominent finding in patients who have been operated with gastric bypass \[[@B4], [@B31]\]. Hypothetically, a central GLP-1 mechanism might play a role for the enhanced lipolysis after GBP. Glucagon stimulates glycogenolysis and fatty acid oxidation in the liver and has been shown also to stimulate lipolysis in adipocytes \[[@B32], [@B33]\]. In patients operated with GBP, a remarkable response with a rise in glucagon following food intake has been observed \[[@B34], [@B35]\]. Possibly, postprandial increases in glucagon levels might contribute to the enhanced mobilization of body fat after GBP surgery.

In conclusion, the mechanism behind an enhanced lipolysis after GBP seems multifactorial. The caloric restriction imposed by the surgical procedure is the main driver of lipolysis, to which altered gastrointestinal signalling, for example, meal-stimulated increases in GLP-1 and glucagon, and sympathetic nerve outflow to the adipose tissue in autonomic nerves conceivably contribute. It is likely that FFAs are utilized as energy source in heart and skeletal muscle and lower the need for glucose, which in turn lowers insulin secretion in the nonfed state and thereby promotes lipid mobilization. Lipolysis might also be stimulated by increased fasting levels of lipolytic hormones, for example, growth hormone, BNP, catecholamines. An increased flux of FFA from adipose tissues depots would promote the maintained triglyceride levels in the liver one month after GBP. To obtain further insights into the phenomenon of enhanced lipolysis, studies of diurnal hormone and catecholamine dynamics could be of interest.
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![Illustration of image data employed from one subject included in the study. Reconstructed fat and water images are shown in (a) and (b), respectively. The horizontal lines delineate the subvolumes analysed in (c) and (d), where the fat- \[fat/(fat+water)\] and water-fraction \[water/(fat+water)\] images calculated and used to estimate total fat and water volumes are shown, respectively. Note that the intensity variations seen in (a) and (b) are removed by the use of fraction images. The intensity in each pixel estimates its absolute fat and water contents, and by integrating the pixel contents, total volumes are obtained. Note that fat infiltration of the liver (greyish and measured to approximately 25%) can be seen in (c).](JOBES2011-959601.001){#fig1}

![Relative mean changes of weight, total fat, total water, and liver fat during the LCD and the GBP months (*n* = 13).](JOBES2011-959601.002){#fig2}

![Individual total body fat volumes measured using prior to one month of LCD, at surgery, and at one month postGBP (*n* = 13). Mean body fat volume is illustrated by the thicker line.](JOBES2011-959601.003){#fig3}

![Liver fat concentrations (%) determined using MRS at the three time points (*n* = 13). The thicker line illustrates mean liver fat concentration.](JOBES2011-959601.004){#fig4}

###### 

Subject characteristics of the 15 females at baseline and after one month of low-calorie diet (LCD) and one month after gastric bypass (GBP).

                                  Baseline         Post LCD                  Post GBP         
  ------------------------------- ---------------- ---------------- -------- ---------------- --------
  Age (years)                     34.7 ± 7.88                                                 
  Weight (kg)                     121.3 ± 13.4     113.9 ± 12.0     \<.001   105.8 ± 12.0     \<.001
  BMI (kg/m^2^)                   42.9 ± 3.02      40.3 ± 2.93      \<.001   37.4 ± 2.99      \<.001
  Total fat Volume (L)            69.3 ± 7.55^a^   64.3 ± 6.85^a^   \<.001   58.0 ± 7.65^a^   \<.001
  Total water Volume (L)          42.9 ± 4.53^a^   40.8 ± 3.82^a^   \<.001   38.8 ± 4.44^a^   \<.001
  VAT (L)                         5.31 ± 0.97^a^   4.91 ± 0.88^a^   .002     4.39 ± 0.73^a^   \<.001
  SAT abd (L)                     21.3 ± 2.93^a^   19.8 ± 2.73^a^   .003     17.8 ± 3.10^a^   \<.001
  Liver fat (%)                   9.72 ± 6.31^a^   5.69 ± 4.24^a^   .001     5.89 ± 3.93^a^   .736
  Liver volume (L)                2.17 ± 0.38^a^   1.90 ± 0.23^a^   .001     1.89 ± 0.28^a^   .841
  Liver fat Volume (mL)           218 ± 154        107 ± 78.0       \<.001   111 ± 70.8       .376
  Hemoglobin (g/L)                139 ± 7.54       140 ± 7.26       .845     136 ± 6.77       .099
  EVF (%)                         41.2 ± 2.40      40.8 ± 2.51      .458     39.3 ± 2.23      .115
  Na (mmol/L)                     136 ± 0.99       137 ± 1.64       .041     139 ± 1.62       .007
  K (mmol/L)                      3.95 ± 0.20      3.67 ± 0.25      .009     3.65 ± 0.23      .793
  Creatinine (umol/L)             58.9 ± 3.75      65.9 ± 6.34      .000     58.7 ± 5.90      .003
  Albumin (g/L)                   41.3 ± 2.26      44.5 ± 3.23      .001     43.3 ± 2.72      .221
  ALT (ukat/L)                    0.43 ± 0.15      0.93 ± 0.60      .007     0.57 ± 0.26      .015
  AST (ukat/L)                    0.47 ± 0.11      0.62 ± 0.23      .045     0.48 ± 0.12      .034
  GT (*μ*kat/L)                   0.65 ± 0.72      0.74 ± 0.81      .119     0.53 ± 0.28      .179
  Glucose (mmol/L)                5.14 ± 0.67      4.73 ± 0.83      .005     5.03 ± 0.49      .082
  Insulin (mU/L)                  22.9 ± 7.82      17.1 ± 8.15      \<.001   13.3 ± 5.52      .096
  HOMA index                      5.32 ± 2.18      3.63 ± 1.93      \<.001   2.99 ± 1.33      .241
  Growth hormone (ug/L)           0.46 ± 0.52      1.05 ± 0.97      .008     1.49 ± 1.11      .146
  Glucagon (pmol/L)               73.4 ± 20.8      69.4 ± 17.9      .149     75.8 ± 18.2      .024
  BNP (ng/L)                      44.7 ± 27.4      46.3 ± 28.4      .847     93.7 ± 71.5      .011
  Leptin (mg/L)                   17.4 ± 4.91      12.8 ± 8.43      .000     10.3 ± 3.29      .001
  Adiponectin (Ug/mL)             7.49 ± 2.97      8.37 ± 8.43      .302     8.13 ± 3.56      .662
  Cholesterol (mmol/L)            4.79 ± 1.14      4.43 ± 1.05      .002     4.29 ± 0.92      .349
  HDL (mmol/L)                    1.08 ± 0.19      0.93 ± 0.15      .001     0.95 ± 0.19      .550
  LDL (mmol/L)                    3.07 ± 0.96      2.85 ± 1.05      .125     2.64 ± 0.84      .145
  LDL/HDL                         2.93 ± 1.10      3.27 ± 1.44      .092     2.95 ± 1.05      .094
  Triglycerides (mmol/L)          2.17 ± 1.28      1.80 ± 0.76      .255     1.80 ± 0.54      1.000
  ApoA1 (g/L)                     1.33 ± 0.14      1.10 ± 0.12      \<.001   1.11 ± 0.11      .829
  ApoB (g/L)                      0.96 ± 0.32      0.89 ± 0.28      .048     0.88 ± 0.25      .775
  ApoB/ApoA1                      0.73 ± 0.25      0.82 ± 0.28      .014     0.79 ± 0.23      .290
  FFA (mmol/L)                    0.58 ± 0.23      0.85 ± 0.33      .011     0.89 ± 0.28      .739
  Beta-hydroxybutyrate (mmol/L)   0.07 ± 0.05      0.31 ± 0.28      .007     0.34 ± 0.22      .613

^a^Data from the 13 subjects who completed the MR investigations. BMI: body mass index, VAT: visceral adipose tissue volume, SAT: subcutaneous adipose tissue volume in the abdominal subvolume, EVF: erythrocyte volume fraction. ALT: alanine transaminase, AST: aspartate aminotransferase, GT: gamma glutamyltransferase, BNP: B-type natriuretic peptide, FFA: free fatty acids.

Statistical significance evaluated from baseline to post-LCD, and post-LCD to post-GBP.

###### 

Relative changes (%) over the low-calorie diet (LCD) and postGBP periods.

                         LCD month         GBP month         *P* value
  ---------------------- ----------------- ----------------- --------------
  Weight / BMI           −6.08 ± 1.77      −7.17 ± 1.60      .148
  Total Fat Volume       −7.11 ± 3.58^a^   −10.0 ± 3.19^a^   .029
  Total Water Volume     −4.82 ± 2.29^a^   −4.98 ± 2.69^a^   .898
  VAT                    −7.28 ± 6.92^a^   −10.3 ± 6.40^a^   .326
  SAT abd                −6.55 ± 6.73^a^   −10.3 ± 5.32^a^   .171
  Liver Fat              −40.6 ± 25.3^a^   +12.4 ± 51.7^a^   .011
  Liver Volume           −12.0 ± 7.54^a^   −0.40 ± 8.33^a^   .013
  Liver Fat Volume       −47.2 ± 24.5      13.6 ± 55.9       .006
  Hemoglobin             0.27 ± 3.73       −2.72 ± 6.17      .195
  EVF                    −0.87 ± 5.04      −3.27 ± 7.81      .409
  Na                     0.79 ± 1.34       1.32 ± 1.62       .473
  K                      −6.78 ± 8.83      −0.19 ± 10.1      .184
  Creatinine             11.9 ± 8.32       −10.4 ± 11.0      \<.001
  Albumin                7.84 ± 7.08       −2.32 ± 7.90      .009
  ALT                    138 ± 180         −26.5 ± 29.3      .007
  AST                    43.1 ± 88.2       −16.4 ± 25.5      .047
  GT                     14.9 ± 38.1       −3.81 ± 39.3      .282
  Glucose                −8.01 ± 8.53      8.01 ± 13.2       .008
  Insulin                −27.0 ± 20.1      −12.5 ± 43.8      .339
  HOMA index             −32.2 ± 22.2      −2.47 ± 60.2      .141
  Growth hormone         348 ± 621         422 ± 1070        .835
  Glucagon               −3.54 ± 17.1      10.6 ± 15.3       .055
  BNP                    34.1 ± 97.5       146 ± 173         .078
  Leptin                 −25.7 ± 14.6      −18.3 ± 19.9      .182
  Adiponectin            16.0 ± 47.3       76.8 ± 310        .504
  Cholesterol            −7.11 ± 7.31      −2.13 ± 11.4      .269
  HDL                    −13.3 ± 12.5      2.46 ± 13.3       .023
  LDL                    −6.91 ± 17.1      −5.23 ± 15.1      .830
  LDL/HDL                12.4 ± 21.2       −7.36 ± 16.6      .043
  Triglycerides          −6.01 ± 37.8      7.10 ± 29.7       .409
  Ap-lipA1               −16.6 ± 8.11      1.09 ± 9.80       .001
  Ap-lipB                −5.97 ± 13.0      0.15 ± 10.8       .268
  ApB/A1                 15.3 ± 20.6       −2.30 ± 14.4      .050 (.0497)
  FFA                    74.4 ± 109        20.9 ± 589        .186
  Beta-hydroxybutyrate   482 ± 651         103 ± 220         .080

^a^Data from the 13 subjects who completed the MR investigations. BMI: body mass index, VAT: visceral adipose tissue volume, SAT: subcutaneous adipose tissue volume in the abdominal subvolume, EVF: erythrocyte volume fraction. ALT: alanine transaminase, AST: aspartate aminotransferase, GT: gamma glutamyltransferase, BNP: B-type natriuretic peptide, FFA: free fatty acids.

Statistical significance evaluated from differences in relative changes over the LCD and GBP months.
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